Torvutatug Samrotecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of torvutatug, a human monoclonal antibody targeting folate receptor alpha (FRa; FolRa; FOLR1) conjugated to samrotecan, a linker conjugated to exatecan, with potential antineoplastic activity. Upon administration of torvutatug samrotecan, the antibody moiety targets and binds to FRa expressed on tumor cells. Upon binding, cellular uptake and linker cleavage, exatecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and generating DNA single- and double-strand breaks, and leading to cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of FRa-expressing tumor cells. FRa is a glycosylphosphatidylinositol linked cell-surface glycoprotein that is widely expressed in certain cancers while its expression is limited in normal tissues.

**Synonyms:** - AZD 5335 - AZD-5335 - AZD5335 - Anti-FRa ADC AZD5335 - Anti-FRa Antibody-drug Conjugate AZD5335 - Anti-folate Receptor Alpha Antibody-drug Conjugate AZD5335 - TORVUTATUG SAMROTECAN